Immunological aspects of cancer chemotherapy

Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516

Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009

Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., et al. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.150 · Cited by 3,399

Calreticulin exposure dictates the immunogenicity of cancer cell death

Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216

Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 1×

IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity

Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896

Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473

A cytokine-mediated link between innate immunity, inflammation, and cancer

Lin, W.-W., & Karin, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31537 · Cited by 1,940

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737

Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma

Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U. S., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,625

Immunity, Inflammation, and Cancer

Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755

The immune contexture in human tumours: impact on clinical outcome

Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496

Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments

Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,023

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565

Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009

Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., et al. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.150 · Cited by 3,399

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079

NF-κB, inflammation, immunity and cancer: coming of age

Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679

Influence of tumour micro-environment heterogeneity on therapeutic response

Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,417

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors

Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898

Nanotechnology for Multimodal Synergistic Cancer Therapy

Fan, W., Yung, B. C., Huang, P., & Chen, X. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00258 · Cited by 1,813

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

Denkert, C., Loibl, S., Noske, A., Roller, M., Müller, B. M., Komor, M., Budczies, J., Darb‐Esfahani, S., Kronenwett, R., Hanusch, C. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7370 · Cited by 1,796

Hallmarks of response, resistance, and toxicity to immune checkpoint blockade

Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

West, H., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H. J., Kopp, H.-G., Daniel, D., McCune, S., Mekhail, T., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30167-6 · Cited by 1,662

Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance

Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., Wu, S., Deng, Y., Zhang, J., & Shao, A. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00193 · Cited by 1,451

Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation

Solinas, G., Germano, G., Mantovani, A., & Allavena, P. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0609385 · Cited by 1,456

Translational biology of osteosarcoma

Kansara, M., Teng, M. W., Smyth, M. J., & Thomas, D. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3838 · Cited by 1,294

5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor Immunity

Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rébé, C., & Ghiringhelli, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3690 · Cited by 1,245

Immunogenic and tolerogenic cell death

Green, D. R., Ferguson, T., Zitvogel, L., & Kroemer, G. (2009) · Nature Reviews Immunology · doi:10.1038/nri2545 · Cited by 1,176

Nanoparticles for Cancer Therapy: Current Progress and Challenges

Gavas, S., Quazi, S., & Karpiński, T. M. (2021) · Nanoscale Research Letters · doi:10.1186/s11671-021-03628-6 · Cited by 1,069

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

Lynch, T. J., Bondarenko, I., Luft, A. V., Serwatowski, P., Barlési, F., Chacko, R. T., Sebastian, M., Neal, J. W., Lu, H., Cuillerot, J.-M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4032 · Cited by 1,013

Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer

Li, K., Shi, H., Zhang, B., Ou, X., Ma, Q., Chen, Y., Shu, P., Li, D., & Wang, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00670-9 · Cited by 1,046

Clinical relevance of host immunity in breast cancer: from TILs to the clinic

Savas, P., Salgado, R., Denkert, C., Sotiriou, C., Darcy, P. K., Smyth, M. J., & Loi, S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.215 · Cited by 890

Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance

Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 901

Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial

Nywening, T. M., Wang‐Gillam, A., Sanford, D. E., Belt, B. A., Panni, R. Z., Cusworth, B. M., Toriola, A. T., Nieman, R., Worley, L. A., Yano, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00078-4 · Cited by 840

Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients

Ooft, S. N., Weeber, F., Dijkstra, K. K., McLean, C. M., Kaing, S., van Werkhoven, E., Schipper, L., Hoes, L., Vis, D. J., van de Haar, J., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aay2574 · Cited by 813

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Kang, Y., Chen, L., Ryu, M., Oh, D., Oh, S. C., Chung, H. C., Lee, K., Omori, T., Shitara, K., Sakuramoto, S., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00692-6 · Cited by 827

Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth

Bruchard, M., Mignot, G., Dérangère, V., Chalmin, F., Chevriaux, A., Végran, F., Boireau, W., Simon, B., Ryffel, B., Connat, J., et al. (2012) · Nature Medicine · doi:10.1038/nm.2999 · Cited by 797

Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy

He, C., Duan, X., Guo, N., Chan, C., Poon, C. J., Weichselbaum, R. R., & Lin, W. (2016) · Nature Communications · doi:10.1038/ncomms12499 · Cited by 759

Turning the corner on therapeutic cancer vaccines

Hollingsworth, R. E., & Jansen, K. (2019) · npj Vaccines · doi:10.1038/s41541-019-0103-y · Cited by 689

Origins of tumor-associated macrophages and neutrophils

Cortez‐Retamozo, V., Etzrodt, M., Newton, A., Rauch, P. J., Chudnovskiy, A., Berger, C., Ryan, R. J. H., Iwamoto, Y., Marinelli, B. S., Gorbatov, R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113744109 · Cited by 702

Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges

Day, C.-P., Merlino, G., & Van Dyke, T. (2015) · Cell · doi:10.1016/j.cell.2015.08.068 · Cited by 676

The secret ally: immunostimulation by anticancer drugs

Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3626 · Cited by 708

Immune parameters affecting the efficacy of chemotherapeutic regimens

Zitvogel, L., Kepp, O., & Kroemer, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.223 · Cited by 686

Metronomic chemotherapy: new rationale for new directions

Pasquier, E., Kavallaris, M., & André, N. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.82 · Cited by 666

Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy

Starobova, H., & Vetter, I. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00174 · Cited by 690

Cytokines and their relationship to the symptoms and outcome of cancer

Seruga, B., Zhang, H., Bernstein, L. J., & Tannock, I. F. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2507 · Cited by 652

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

Reck, M., Bondarenko, I., Luft, A. V., Serwatowski, P., Barlési, F., Chacko, R. T., Sebastian, M., Lü, H., Cuillerot, J.-M., & Lynch, T. J. (2012) · Annals of Oncology · doi:10.1093/annonc/mds213 · Cited by 613

Role of Immunotherapy in Triple-Negative Breast Cancer

Keenan, T. E., & Tolaney, S. M. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7554 · Cited by 625

CD4+ Lymphoid Tissue-Inducer Cells Promote Innate Immunity in the Gut

Sonnenberg, G. F., Monticelli, L. A., Elloso, M. M., Fouser, L. A., & Artis, D. (2010) · Immunity · doi:10.1016/j.immuni.2010.12.009 · Cited by 591

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

Bockorny, B., Semenisty, V., Macarulla, T. M., Borazanci, E. H., Wolpin, B. M., Stemmer, S. M., Golan, T., Geva, R., Borad, M. J., Pedersen, K. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0880-x · Cited by 563

Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors

Gonçalves, B., Ferreira, C., Alves, C. T., Henriques, M., Azeredo, J., & Silva, S. (2016) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2015.1091805 · Cited by 669

The gut microbiota influences anticancer immunosurveillance and general health

Routy, B., Gopalakrishnan, V., Daillère, R., Zitvogel, L., Wargo, J. A., & Kroemer, G. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0006-2 · Cited by 523

Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer

Peng, J., Hamanishi, J., Matsumura, N., Abiko, K., Murat, K., Baba, T., Yamaguchi, K., Horikawa, N., Hosoe, Y., Murphy, S. K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3098 · Cited by 525

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

Balachandran, V. P., Cavnar, M. J., Zeng, S., Bamboat, Z. M., Ocuin, L. M., Obaid, H., Sorenson, E. C., Popow, R., Ariyan, C. E., Rossi, F., et al. (2011) · Nature Medicine · doi:10.1038/nm.2438 · Cited by 541

Human Solid Tumors Contain High Endothelial Venules: Association with T- and B-Lymphocyte Infiltration and Favorable Prognosis in Breast Cancer

Martinet, L., Garrido, I., Filleron, T., Guellec, S. L., Bellard, E., Fournié, J., Rochaix, P., & Girard, J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0431 · Cited by 548

Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non–Small Cell Lung Cancer

Li, B., Cui, Y., Diehn, M., & Li, R. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1609 · Cited by 514

Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents

Buddingh, E. P., Kuijjer, M. L., Duim, R. A. J., Bürger, H., Agelopoulos, K., Myklebost, O., Serra, M., Mertens, F., Hogendoorn, P. C. W., Lankester, A. C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2047 · Cited by 508

Cancer Immunotherapy by Dendritic Cells

Melief, C. J. M. (2008) · Immunity · doi:10.1016/j.immuni.2008.08.004 · Cited by 509

Tumor Microenvironment‐Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade

Zhou, F., Feng, B., Yu, H., Wang, D., Wang, T., Ma, Y., Wang, S., & Li, Y. (2019) · Advanced Materials · doi:10.1002/adma.201805888 · Cited by 503

Molecular characteristics of immunogenic cancer cell death

Tesnière, A., Panaretakis, T., Kepp, O., Apétoh, L., Ghiringhelli, F., Zitvogel, L., & Kroemer, G. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402269 · Cited by 509

Myeloid-Derived Suppressor Cells

Parker, K. H., Beury, D. W., & Ostrand‐Rosenberg, S. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.04.002 · Cited by 490

Leukocyte composition of human breast cancer

Ruffell, B., Au, A., Rugo, H. S., Esserman, L. J., Hwang, E. S., & Coussens, L. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104303108 · Cited by 489

Multiple Drug Resistance Mechanisms in Cancer

Baguley, B. C. (2010) · Molecular Biotechnology · doi:10.1007/s12033-010-9321-2 · Cited by 481

The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment

Kim, S. K., & Cho, S. W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.868695 · Cited by 502

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice

Ramakrishnan, R., Assudani, D., Nagaraj, S., Hunter, T. B., Cho, H.-I., Antonia, S. J., Altiok, S., Celis, E., & Gabrilovich, D. I. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40269 · Cited by 476

Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient

Jiménez-Sánchez, A., Memon, D., Pourpe, S., Veeraraghavan, H., Li, Y., Vargas, H. A., Gill, M. B., Park, K. J., Zivanovic, O., Konner, J. A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.025 · Cited by 456

Binary Cooperative Prodrug Nanoparticles Improve Immunotherapy by Synergistically Modulating Immune Tumor Microenvironment

Feng, B., Zhou, F., Hou, B., Wang, D., Wang, T., Fu, Y., Ma, Y., Yu, H., & Li, Y. (2018) · Advanced Materials · doi:10.1002/adma.201803001 · Cited by 451

Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Rizvi, N. A., Hellmann, M. D., Brahmer, J. R., Juergens, R. A., Borghaei, H., Gettinger, S. N., Chow, L. Q. M., Gerber, D. E., Laurie, S. A., Goldman, J. W., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9861 · Cited by 450

Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities

Balachandran, V. P., Beatty, G. L., & Dougan, S. K. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.038 · Cited by 444

CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer

Liu, S., Lachapelle, J., Leung, S. C. Y., Gao, D., Foulkes, W. D., & Nielsen, T. O. (2012) · Breast Cancer Research · doi:10.1186/bcr3148 · Cited by 447

The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?

Savio, L. E. B., de Andrade Mello, P., da Silva, C. G., & Coutinho-Silva, R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00052 · Cited by 437

Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon–independent apoptosis in human melanoma cells

Besch, R., Poeck, H., Hohenauer, T., Senft, D., Häcker, G. A., Berking, C., Hornung, V., Endres, S., Ruzicka, T., Rothenfußer, S., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37155 · Cited by 434

Control of autophagy by oncogenes and tumor suppressor genes

Maiuri, M. C., Tasdemir, E., Criollo, A., Morselli, E., Vicencio, J. M., Carnuccio, R., & Kroemer, G. (2008) · Cell Death and Differentiation · doi:10.1038/cdd.2008.131 · Cited by 447

Amphiregulin Enhances Regulatory T Cell-Suppressive Function via the Epidermal Growth Factor Receptor

Zaiss, D. M. W., van Loosdregt, J., Gorlani, A., Bekker, C. P. J., Gröne, A., Sibilia, M. C., Henegouwen, P. M. P. V. B. E., Roovers, R. C., Coffer, P. J., & Sijts, A. J. A. M. (2013) · Immunity · doi:10.1016/j.immuni.2012.09.023 · Cited by 433

Cytokines as biomarkers of nanoparticle immunotoxicity

Elsabahy, M., & Wooley, K. L. (2013) · Chemical Society Reviews · doi:10.1039/c3cs60064e · Cited by 417

Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity

Biase, S. D., Lee, C. D., Brandhorst, S., Manes, B., Buono, R., Cheng, C., Cacciottolo, M., Martín‐Montalvo, A., de Cabo, R., Wei, M., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.005 · Cited by 418

Chemotherapy: a double-edged sword in cancer treatment

Behranvand, N., Nasri, F., Emameh, R. Z., Khani, P., Hosseini, A., Garssen, J., & Falak, R. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03013-3 · Cited by 454

Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway

Zitvogel, L., Kepp, O., Senovilla, L., Menger, L., Chaput, N., & Kroemer, G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2891 · Cited by 401

IKK/NF‐κB and STAT3 pathways: central signalling hubs in inflammation‐mediated tumour promotion and metastasis

Bollrath, J., & Greten, F. R. (2009) · EMBO Reports · doi:10.1038/embor.2009.243 · Cited by 384

Tumor Cell Death and ATP Release Prime Dendritic Cells and Efficient Anticancer Immunity

Aymeric, L., Apétoh, L., Ghiringhelli, F., Tesnière, A., Martins, I., Kroemer, G., Smyth, M. J., & Zitvogel, L. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3566 · Cited by 401

Anti- and pro-tumor functions of autophagy

Morselli, E., Galluzzi, L., Kepp, O., Vicencio, J. M., Criollo, A., Maiuri, M. C., & Kroemer, G. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2009.01.006 · Cited by 393

Mechanisms regulating T-cell infiltration and activity in solid tumors

Lanitis, E., Dangaj, D., Irving, M., & Coukos, G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx238 · Cited by 369

Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis

Schiavoni, G., Sistigu, A., Valentini, M., Mattei, F., Sestili, P., Spadaro, F., Sanchez, M., Lorenzi, S., D'Urso, M. T., Belardelli, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2788 · Cited by 362

Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities

Kim, T. K., Vandsemb, E. N., Herbst, R. S., & Chen, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00493-5 · Cited by 361

Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer

West, N. R., Milne, K., Truong, P. T., Macpherson, N. A., Nelson, B. H., & Watson, P. H. (2011) · Breast Cancer Research · doi:10.1186/bcr3072 · Cited by 365

Chemotherapy Alters Monocyte Differentiation to Favor Generation of Cancer-Supporting M2 Macrophages in the Tumor Microenvironment

Dijkgraaf, E. M., Heusinkveld, M., Tummers, B., Vogelpoel, L. T. C., Goedemans, R., Jha, V., Nortier, J. W. R., Welters, M. J. P., Kroep, J. R., & van der Burg, S. H. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3542 · Cited by 346

The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death

Panaretakis, T., Joza, N., Modjtahedi, N., Tesniere, A., Vitale, I., Durchschlag, M., Fimia, G. M., Kepp, O., Piacentini, M., Froehlich, K.-U., et al. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.67 · Cited by 344

Tumor organoids: Opportunities and challenges to guide precision medicine

Veninga, V., & Voest, E. E. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.020 · Cited by 339

Interaction of tumor-associated macrophages and cancer chemotherapy

Larionova, I., Cherdyntseva, N., Liu, T., Patysheva, M., Rakina, M., & Kzhyshkowska, J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1596004 · Cited by 322

Interferon‐γ reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor‐associated macrophages

Duluc, D., Corvaisier, M., Blanchard, S., Catala, L., Descamps, P., Gamelin, E. C., Ponsoda, S., Delneste, Y., Hebbar, M., & Jeannin, P. (2009) · International Journal of Cancer · doi:10.1002/ijc.24401 · Cited by 328

DNA-Containing Exosomes Derived from Cancer Cells Treated with Topotecan Activate a STING-Dependent Pathway and Reinforce Antitumor Immunity

Kitai, Y., Kawasaki, T., Sueyoshi, T., Kobiyama, K., Ishii, K. J., Zou, J. P., Akira, S., Matsuda, T., & Kawai, T. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601694 · Cited by 334

Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy

Wu, J., & Waxman, D. J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.050 · Cited by 329

Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)

Boku, N., Ryu, M., Kato, K., Chung, H. C., Minashi, K., Lee, K.-W., Cho, H., Kang, W. K., Komatsu, Y., Tsuda, M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy540 · Cited by 316

Mitochondrial gateways to cancer

Galluzzi, L., Morselli, E., Kepp, O., Vitale, I., Rigoni, A., Vacchelli, E., Michaud, M., Zischka, H., Castedo, M., & Kroemer, G. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2009.08.002 · Cited by 303

Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy

Kepp, O., Galluzzi, L., Martins, I., Schlemmer, F., Adjemian, S., Michaud, M., Sukkurwala, A. Q., Menger, L., Zitvogel, L., & Kroemer, G. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9273-4 · Cited by 303

Metal-based anticancer agents as immunogenic cell death inducers: the past, present, and future

Sen, S., Won, M., Levine, M. S., Noh, Y., Sedgwick, A. C., Kim, J. S., Sessler, J. L., & Arambula, J. F. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00417d · Cited by 297

CD40 stimulation obviates innate sensors and drives T cell immunity in cancer

Byrne, K. T., & Vonderheide, R. H. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.058 · Cited by 282

Combined immune checkpoint blockade as a therapeutic strategy for BRCA1 -mutated breast cancer

Nolan, E., Savas, P. S., Policheni, A. N., Darcy, P. K., Vaillant, F., Mintoff, C., Dushyanthen, S., Mansour, M., Pang, J., Fox, S. B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal4922 · Cited by 297

Mechanisms of immune evasion in breast cancer

Bates, J. P., Derakhshandeh, R., Jones, L. P., & Webb, T. J. (2018) · BMC Cancer · doi:10.1186/s12885-018-4441-3 · Cited by 305

Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6Clow F4/80+ Extratumoral Macrophages

Beatty, G. L., Winograd, R., Evans, R. A., Long, K. B., Luque, S. L., Lee, J. W., Clendenin, C., Gladney, W. L., Knoblock, D. M., Guirnalda, P. D., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.010 · Cited by 297

Bleomycin-Based Electrochemotherapy: Clinical Outcome from a Single Institution’s Experience with 52 Patients

Campana, L. G., D, S. M. M., Basso, M., Puccetti, O., Salvo, G. L. D., Chiarion‐Sileni, V., Vecchiato, A., Corti, L., Rossi, C. R., & Nitti, D. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0204-8 · Cited by 290

Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up

Adams, S., Diamond, J. R., Hamilton, E. P., Pohlmann, P. R., Tolaney, S. M., Chang, C., Zhang, W., Iizuka, K., Foster, P., Molinero, L. L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5152 · Cited by 293

The immune system and response to HER2-targeted treatment in breast cancer

Bianchini, G., & Gianni, L. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70477-7 · Cited by 287

Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?

Apétoh, L., Ladoire, S., Coukos, G., & Ghiringhelli, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv209 · Cited by 286

Chemotherapy induces ATP release from tumor cells

Martins, I., Tesnière, A., Kepp, O., Michaud, M., Schlemmer, F., Senovilla, L., Séror, C., Métivier, D., Perfettini, J., Zitvogel, L., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.22.10026 · Cited by 300

Autophagy regulates selective HMGB1 release in tumor cells that are destined to die

Thorburn, J., Horita, H., Redzic, J., Hansen, K., Frankel, A. E., & Thorburn, A. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.143 · Cited by 268

Modulation of Pulmonary Microbiota by Antibiotic or Probiotic Aerosol Therapy: A Strategy to Promote Immunosurveillance against Lung Metastases

Le Noci, V., Guglielmetti, S., Arioli, S., Camisaschi, C., Bianchi, F., Sommariva, M., Storti, C., Triulzi, T., Castelli, C., Balsari, A., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.090 · Cited by 270

Polymeric nanoparticles promote macrophage reversal from M2 to M1 phenotypes in the tumor microenvironment

Wang, Y., Lin, Y., Qiao, S., An, H., Ma, Y., Qiao, Z., Rajapaksha, R. P. Y. J., & Wang, H. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.09.034 · Cited by 268

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.67 · Cited by 951

Immune Effects of Conventional Cancer Therapeutics

Demaria, S., & Galluzzi, L. (2018) · Springer Publishing Company eBooks · doi:10.1891/9781617052736.0022

Activation of Immune-Mediated Tumor Cell Death by Chemotherapy

McCoy, M. J., Nowak, A. K., & Lake, R. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5847-0_14

Prerequisites for the Antitumor Vaccine-Like Effect of Chemotherapy and Radiotherapy

Hannani, D., Sistigu, A., Kepp, O., Galluzzi, L., Kroemer, G., & Zitvogel, L. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e3182325d4d · Cited by 88

Immunogenic effects of chemotherapy-induced tumor cell death

Wang, Y., Fletcher, R., Yu, J., & Zhang, L. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.003 · Cited by 328